Gamma Biologicals Adds Donor Testing to ReACT Product Line
FDA Approves Addition to Company's Licensed Reagent Red Cell Products
HOUSTON--(BUSINESS WIRE)--April 23, 1998--Gamma Biologicals Inc. (Amex:GBL - news) has received FDA approval to market ReACT(tm) Screening Cell Pool. Screening of blood donors is a required routine test on all donations. Previously, the company's reagent red cell products for the ReACT were intended for patients who might receive blood transfusions.
''This newly approved product allows the technologist to screen large numbers of donors quickly, saving time and money. In addition to extending our ReACT product line, we have opened a new market for the estimated 12 million annual blood donations in the United States alone,'' said David E. Hatcher, Gamma's chairman, president and chief executive officer.
''Six additional tests using the patented ReACT adherence technology are under development,'' continued Hatcher, ''and our long-term plan is to expand the ReACT system to include a full line of testing products. These products under development will require FDA approval prior to marketing.''
biz.yahoo.com
Gamma Bio gets FDA ok for blood screener
HOUSTON, April 23 (Reuters) - Gamma Biologicals Inc. said Thursday it received approval from the Food and Drug Administration to market its ReACT Screening Cell Pool.
The company said the blood donor screening product allows technologists to screen large numbers of donors quickly, saving time and money.
Gamma also said that in addition to extending its ReACT product line, it opened a new market for the estimated 12 million annual blood donations in the United States.
biz.yahoo.com |
